InterMune kept at market perform by JMP

InterMune, Inc. was reiterated by JMP Securities analyst Adam Cutler at market perform. The company reported first-quarter GAAP loss per share of $0.39, compared with the analyst's loss per share estimate of $0.23 and the Street's loss estimate of $0.26. Revenue (made up entirely of Actimmune sales) of $24.4 million was below JMP's forecast of $25.0 million and the Street's estimate of $25.9 million. Shares of the Brisbane, Calif., biopharmaceutical company were down 48 cents, or 2.90%, at $15.99 on volume of 586,772 shares versus the three-month running average of 399,603 shares. (Nasdaq: ITMN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.